AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28482641 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 9
Study 25964310 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cooling at 0.5°C below body temperature
Number of subjects: 73
Study 23098160 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime regimen
Number of subjects: 2899
Study 23098160 — intervention group
Group type: COMPARATOR
Intervention: Upon-awakening regimen
Number of subjects: 2899
Study 23098160 — intervention group
Group type: COMPARATOR
Intervention: BID regimen
Number of subjects: 2899
Study 21574730 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased positive partner support
Number of subjects: 81
Study 21574730 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased negative partner support
Number of subjects: 81
Study 18279623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine and morphine through thoracic epidural preoperatively (group PE)
Number of subjects: 105
Study 18279623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine and morphine through thoracic epidural postoperatively (group E)
Number of subjects: 105
Study 18279623 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of fentanyl postoperatively (group IV)
Number of subjects: 105
Study 15970448 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg)
Number of subjects: 14
Study 15970448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 14521679 — intervention group
Group type: EXPERIMENTAL
Intervention: Action research methodology
Number of subjects: 0
Study 14521679 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11112957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 6
Study 8955966 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (300 micrograms)
Number of subjects: 60
Study 8955966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clonidine (300 micrograms)
Number of subjects: 60
Study 8955966 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 1573044 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg)
Number of subjects: 15
Study 1573044 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone (20 mg)
Number of subjects: 15
Study 1573044 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone (10 mg)
Number of subjects: 15
Study 1573044 — intervention group
Group type: EXPERIMENTAL
Intervention: secobarbital (100 mg)
Number of subjects: 15
Study 1573044 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 3889230 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with methotrexate and leucovorin followed by regional therapy and additional methotrexate courses every three months for one year.
Number of subjects: 82
Study 3889230 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with a combination of Adriamycin and cisplatin every three weeks for four cycles after the first 35 patients.
Number of subjects: 82
Study 3889230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic categories based on expected outcome for each specific tumor site and stage.
Number of subjects: 82
Study 29220534 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture group (AcG)
Number of subjects: 75
Study 29220534 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group (ShG)
Number of subjects: 75
Study 29220534 — intervention group
Group type: COMPARATOR
Intervention: Simulated acupuncture group (SiG)
Number of subjects: 75
Study 27194493 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA IV and IA group (1 g IV preoperatively and 3 g IA postoperatively)
Number of subjects: 60
Study 27194493 — intervention group
Group type: COMPARATOR
Intervention: TXA IV and placebo group (1 g IV preoperatively and 100 mL saline IA)
Number of subjects: 60
Study 27194493 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA IV and IA group
Number of subjects: 60
Study 27194493 — intervention group
Group type: COMPARATOR
Intervention: TXA IV and placebo group
Number of subjects: 60
Study 27194493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 24915800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg.kg(‐1) loading dose followed by 0.5 μg.kg(‐1).h(‐1) infusion)
Number of subjects: 100
Study 24915800 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (bolus and infusion of equivalent volume)
Number of subjects: 100
Study 23059920 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF varnish
Number of subjects: 379
Study 23059920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 20660548 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive continuous positive airway pressure (nCPAP) via helmet
Number of subjects: 20
Study 20660548 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive continuous positive airway pressure (nCPAP) via facial mask
Number of subjects: 20
Study 18999175 — intervention group
Group type: EXPERIMENTAL
Intervention: New analytical method for EHR data
Number of subjects: 0
Study 16500052 — intervention group
Group type: COMPARATOR
Intervention: CEE 0.625mg/day and placebo
Number of subjects: 226
Study 16500052 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625mg/day and fenretinide 100mg/bid
Number of subjects: 226
Study 16500052 — intervention group
Group type: COMPARATOR
Intervention: E2 50microg/day and placebo
Number of subjects: 226
Study 16500052 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 50microg/day and fenretinide
Number of subjects: 226
Study 14651279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental-bonding agent (Solist) followed by resin composite (Ecusit)
Number of subjects: 24
Study 14651279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental adhesive (Prompt) and resin composite (Pertac II)
Number of subjects: 24
Study 14651279 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional calcium hydroxide (Dycal) plus resin composite (Ecusit)
Number of subjects: 24
Study 14651279 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-curing calcium hydroxide (Ultrablend Plus) and amalgam (Dentsply)
Number of subjects: 24
Study 11040229 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 30
Study 11040229 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensives and group A hypertensives)
Number of subjects: 30
Study 8687150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (Nolvadex) for at least 3 years
Number of subjects: 81
Study 8687150 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen
Number of subjects: 81
Study 8687150 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 81
Study 8687150 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen or chemotherapy plus tamoxifen
Number of subjects: 81
Study 8687150 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 81
Study 1534581 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 15
Study 1534581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6441224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid 1.0 g
Number of subjects: 141
Study 6441224 — intervention group
Group type: COMPARATOR
Intervention: Penicillin 4.8 X 10(6) units plus 1.0 g of probenecid
Number of subjects: 141
Study 30616462 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric H. pylori treatment plus periodontal therapy
Number of subjects: 698
Study 30616462 — intervention group
Group type: COMPARATOR
Intervention: Gastric H. pylori treatment alone
Number of subjects: 698
Study 29489568 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Physical Therapy (PT) for 3 weeks
Number of subjects: 119
Study 29489568 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 119
Study 27246405 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training + Mindfulness Meditation (GMT+MM)
Number of subjects: 32
Study 27246405 — intervention group
Group type: COMPARATOR
Intervention: Control (no-intervention)
Number of subjects: 32
Study 23975119 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention group with additional guidance for sun-protection
Number of subjects: 395
Study 23975119 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 395
Study 22311995 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-targeted intervention (massage and humor therapy)
Number of subjects: 171
Study 22311995 — intervention group
Group type: EXPERIMENTAL
Intervention: Child and parent intervention (massage and relaxation/imagery)
Number of subjects: 171
Study 22311995 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 171
Study 20604800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (LGG, 10^10 colony forming units)
Number of subjects: 131
Study 20604800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 17657948 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihomotoxic therapy
Number of subjects: 40
Study 16156884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 160
Study 16156884 — intervention group
Group type: COMPARATOR
Intervention: Protease Inhibitor (PI)
Number of subjects: 160
Study 11914565 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml of crystalloid solution for preloading (Group A)
Number of subjects: 22
Study 11914565 — intervention group
Group type: COMPARATOR
Intervention: 15 ml/kg of crystalloid solution for preloading (Group B)
Number of subjects: 22
Study 11914565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 22
Study 10023505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 10)
Number of subjects: 19
Study 10023505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (n = 9)
Number of subjects: 19
Study 7588161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (3 days)
Number of subjects: 44
Study 7588161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 44
Study 7588161 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 2260153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 120 mg orally
Number of subjects: 871
Study 2260153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871
Study 6105024 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard breakfast
Number of subjects: 0
Study 6105024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 0
Study 6105024 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose
Number of subjects: 0
Study 31191790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression along with conventional treatment
Number of subjects: 89
Study 31191790 — intervention group
Group type: COMPARATOR
Intervention: Cold-pack treatment along with conventional treatment
Number of subjects: 89
Study 29257757 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation containing buradae sandal safaid, safoofe maghze tukhme bakayin, safoofe khaste tamar hindi and safoofe shakkar safaid, 10 g B.D for 21 days
Number of subjects: 0
Study 29257757 — intervention group
Group type: COMPARATOR
Intervention: Combination of azithromycin, fluconazole and secnidazole, single dose
Number of subjects: 0
Study 26549488 — intervention group
Group type: EXPERIMENTAL
Intervention: TASK II intervention (n=123)
Number of subjects: 254
Study 26549488 — intervention group
Group type: COMPARATOR
Intervention: Information, support, and referral group (n=131)
Number of subjects: 254
Study 24293555 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (SBT) group
Number of subjects: 139
Study 24293555 — intervention group
Group type: COMPARATOR
Intervention: No spontaneous breathing trial (no-SBT) group
Number of subjects: 139
Study 22058347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine diacetate
Number of subjects: 60
Study 22058347 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% povidone-iodine
Number of subjects: 60
Study 22058347 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline control
Number of subjects: 60
Study 20084307 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with 1.8mL of lidocaine 2% with epinephrine 1:100,000
Number of subjects: 31
Study 20084307 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia with 1.8mL of lidocaine 2% without epinephrine
Number of subjects: 31
Study 16906625 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation audiotape
Number of subjects: 69
Study 16906625 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized audiotape
Number of subjects: 69
Study 16906625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both audiotapes
Number of subjects: 69
Study 15118481 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 28
Study 15118481 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 28
Study 11915783 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH carbohydrate diet (greater than 70% of daily energy intake from CHO)
Number of subjects: 12
Study 11915783 — intervention group
Group type: COMPARATOR
Intervention: LOW carbohydrate diet (less than 10% of daily energy intake from CHO)
Number of subjects: 12
Study 9567151 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine/physostigmine
Number of subjects: 12
Study 9567151 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine/NaCl
Number of subjects: 12
Study 9567151 — intervention group
Group type: COMPARATOR
Intervention: racemic ketamine
Number of subjects: 12
Study 9567151 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine
Number of subjects: 12
Study 8045133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem
Number of subjects: 1091
Study 8045133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesigyna
Number of subjects: 1091
Study 8045133 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1091
Study 2577393 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (q.i.d. 300 mg)
Number of subjects: 8
Study 2577393 — intervention group
Group type: COMPARATOR
Intervention: Cephradine (q.i.d. 250 mg)
Number of subjects: 8
Study 31253489 — intervention group
Group type: EXPERIMENTAL
Intervention: ExT1D (online educational exercise tool)
Number of subjects: 32
Study 27636247 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 kVp/NI, 60
Number of subjects: 36
Study 27636247 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp/NI, 65
Number of subjects: 36
Study 27636247 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp/NI, 70
Number of subjects: 36
Study 27636247 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp/NI, 20 (control)
Number of subjects: 36
Study 25264154 — intervention group
Group type: EXPERIMENTAL
Intervention: INSURE (intubate‐surfactant‐extubate)
Number of subjects: 60
Study 25264154 — intervention group
Group type: COMPARATOR
Intervention: NCPAP alone
Number of subjects: 60
Study 22372918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-CHW home visitation
Number of subjects: 530
Study 22372918 — intervention group
Group type: COMPARATOR
Intervention: Standard community care (CC) including nurse home visitation
Number of subjects: 530
Study 21825006 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib in combination with fractionated radiotherapy
Number of subjects: 0
Study 21825006 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib alone or in combination with fractionated radiotherapy
Number of subjects: 0
Study 21825006 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 19546759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine pericardium graft
Number of subjects: 94
Study 19546759 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy alone
Number of subjects: 94
Study 16442874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition information program targeting protein consumption
Number of subjects: 82
Study 16442874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 82
Study 15544709 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vapocoolant Fluori‐Methane (FM)
Number of subjects: 185
Study 15544709 — intervention group
Group type: COMPARATOR
Intervention: Cold saline placebo
Number of subjects: 185
Study 11764063 — intervention group
Group type: EXPERIMENTAL
Intervention: Interapy treatment (experimental condition)
Number of subjects: 25
Study 11764063 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 25
Study 9338731 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (alpha1-adrenergic antagonist)
Number of subjects: 134
Study 9338731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 8239013 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 50 micrograms.kg‐1.min‐1
Number of subjects: 30
Study 8239013 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 75 micrograms.kg‐1.min‐1
Number of subjects: 30
Study 8239013 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 100 micrograms.kg‐1.min‐1
Number of subjects: 30
Study 8239013 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial bolus of propofol (2 mg.kg‐1)
Number of subjects: 30
Study 8239013 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (all doses)
Number of subjects: 30
Study 3300953 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 120
Study 3300953 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (six cycles of vincristine, doxorubicin, and cyclophosphamide)
Number of subjects: 120
Study 3300953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 120
Study 3300953 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole immunotherapy (150 mg/day, on 2 consecutive days weekly)
Number of subjects: 120
Study 3300953 — intervention group
Group type: COMPARATOR
Intervention: Control group (no levamisole)
Number of subjects: 120
Study 28811076 — intervention group
Group type: EXPERIMENTAL
Intervention: 8mg dexamethasone
Number of subjects: 60
Study 28811076 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg methylprednisolone
Number of subjects: 60
Study 28811076 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 60
Study 26120010 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg once daily)
Number of subjects: 64
Study 26120010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol/norgestimate (0.035/0.25 mg once daily)
Number of subjects: 64
Study 24833247 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous Window Needle Guide (VWING)
Number of subjects: 54
Study 23106930 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 131
Study 23106930 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 131
Study 23106930 — intervention group
Group type: COMPARATOR
Intervention: Both methadone and buprenorphine
Number of subjects: 131
Study 20106825 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (CsA)
Number of subjects: 1645
Study 20106825 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (Tac)
Number of subjects: 1645
Study 20106825 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus (SRL)
Number of subjects: 1645
Study 20106825 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cyclosporine (CsA)
Number of subjects: 1645
Study 20106825 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cyclosporine without induction
Number of subjects: 1645
Study 17651705 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 39
Study 17651705 — intervention group
Group type: COMPARATOR
Intervention: High-dose olanzapine (up to 30 mg/day)
Number of subjects: 39
Study 17651705 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine and High-dose olanzapine
Number of subjects: 39
Study 15653968 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow transtracheal insufflation of oxygen-enriched air at 15 L/min (fraction of inspired oxygen, 0.37)
Number of subjects: 14
Study 15653968 — intervention group
Group type: COMPARATOR
Intervention: Low-flow transtracheal insufflation of oxygen at 1.5 L/min
Number of subjects: 14
Study 12437797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 32
Study 12437797 — intervention group
Group type: COMPARATOR
Intervention: Non-directive supportive counselling (SC)
Number of subjects: 32
Study 10841003 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction rule based on sulfonylurea Rx, insulin Rx, duration of diabetes, and fasting glucose levels
Number of subjects: 557
Study 10841003 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction rule
Number of subjects: 557
Study 9347199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion alone
Number of subjects: 19
Study 9347199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol with propranolol
Number of subjects: 19
Study 9347199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol with phentolamine
Number of subjects: 19
Study 9347199 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion alone
Number of subjects: 19
Study 9347199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion
Number of subjects: 19
Study 8227867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollister‐Stier lancet
Number of subjects: 0
Study 8227867 — intervention group
Group type: EXPERIMENTAL
Intervention: ALK Laboratories lancet
Number of subjects: 0
Study 8227867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcated needle prick
Number of subjects: 0
Study 8227867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcated needle puncture
Number of subjects: 0